{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:52:03Z","timestamp":1789213923790,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100019434","name":"NIHR Exeter Clinical Research Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.bone.2016.08.010","type":"journal-article","created":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T07:11:30Z","timestamp":1471072290000},"page":"94-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study"],"prefix":"10.1016","volume":"92","author":[{"given":"F.","family":"Gossiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hoyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.V.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.E.","family":"Naylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2016.08.010_bb0005","first-page":"1","volume":"17","year":"2000","journal-title":"NIH Consens. Statement"},{"issue":"2","key":"10.1016\/j.bone.2016.08.010_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/s10165-011-0530-8","article-title":"Regulation of osteoclast function","volume":"22","author":"Nakamura","year":"2012","journal-title":"Mod. Rheumatol. Jpn Rheum. Assoc."},{"issue":"6937","key":"10.1016\/j.bone.2016.08.010_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bone.2016.08.010_bb0020","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0301-472X(99)00061-2","article-title":"Cell biology of the osteoclast","volume":"27","author":"Roodman","year":"1999","journal-title":"Exp. Hematol."},{"issue":"5","key":"10.1016\/j.bone.2016.08.010_bb0025","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1084\/jem.178.5.1733","article-title":"Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts","volume":"178","author":"Fuller","year":"1993","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bone.2016.08.010_bb0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bone.2016.08.010_bb0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.191.2.275","article-title":"Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF\/RANKL-RANK interaction","volume":"191","author":"Kobayashi","year":"2000","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.bone.2016.08.010_bb0040","doi-asserted-by":"crossref","first-page":"775","DOI":"10.4049\/jimmunol.138.3.775","article-title":"Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption","volume":"138","author":"Thomson","year":"1987","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"issue":"6774","key":"10.1016\/j.bone.2016.08.010_bb0045","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/35004599","article-title":"A clonogenic common myeloid progenitor that gives rise to all myeloid lineages","volume":"404","author":"Akashi","year":"2000","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bone.2016.08.010_bb0050","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1189\/jlb.0905522","article-title":"Detection and properties of the human proliferative monocyte subpopulation","volume":"79","author":"Clanchy","year":"2006","journal-title":"J. Leukoc. Biol."},{"issue":"2 Suppl","key":"10.1016\/j.bone.2016.08.010_bb0055","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1016\/j.jaci.2007.07.030","article-title":"3. Adhesion molecules and receptors","volume":"121","author":"Smith","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.bone.2016.08.010_bb0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jbmr.1739","article-title":"Negative regulation of osteoclast precursor differentiation by CD11b and beta2 integrin-B-cell lymphoma 6 signaling","volume":"28","author":"Park-Min","year":"2013","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.08.010_bb0065","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","author":"Naylor","year":"2015","journal-title":"Osteoporos. Int. J. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA."},{"issue":"10","key":"10.1016\/j.bone.2016.08.010_bb0070","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","article-title":"Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study","volume":"22","author":"Chapurlat","year":"2007","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.08.010_bb0075","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2016.08.010_bb0080","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.bone.2005.07.023","article-title":"Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy","volume":"38","author":"Leu","year":"2006","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2016.08.010_bb0085","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/mol.105.020776","article-title":"Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis","volume":"69","author":"Thompson","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"32","key":"10.1016\/j.bone.2016.08.010_bb0090","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr. Pharm. Des."},{"issue":"9","key":"10.1016\/j.bone.2016.08.010_bb0095","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E","article-title":"The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis","volume":"44","author":"Frith","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.bone.2016.08.010_bb0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2016.08.010_bb0105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bone.2011.02.011","article-title":"Bisphosphonates for postmenopausal osteoporosis","volume":"49","author":"Eastell","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2016.08.010_bb0110","first-page":"27","article-title":"Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix","volume":"1","author":"Boonekamp","year":"1986","journal-title":"Bone Miner."},{"issue":"6","key":"10.1016\/j.bone.2016.08.010_bb0115","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/1566524023362104","article-title":"Bisphosphonate mechanism of action","volume":"2","author":"Rodan","year":"2002","journal-title":"Curr. Mol. Med."},{"issue":"4","key":"10.1016\/j.bone.2016.08.010_bb0120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S8756-3282(97)00006-9","article-title":"Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice","volume":"20","author":"van Beek","year":"1997","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2016.08.010_bb0125","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002239900519","article-title":"Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces","volume":"63","author":"Colucci","year":"1998","journal-title":"Calcif. Tissue Int."},{"issue":"10","key":"10.1016\/j.bone.2016.08.010_bb0130","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00198-009-1129-1","article-title":"Alendronate reduces osteoclast precursors in osteoporosis","volume":"21","author":"D'Amelio","year":"2010","journal-title":"Osteoporos. Int. J. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA."},{"issue":"1","key":"10.1016\/j.bone.2016.08.010_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-012-9654-x","article-title":"No reduction in circulating preosteoclasts 18months after treatment with zoledronate: analysis from a randomized placebo controlled trial","volume":"92","author":"Dalbeth","year":"2013","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.bone.2016.08.010_bb0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/8756-3282(95)00448-3","article-title":"Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy","volume":"18","author":"Sauty","year":"1996","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2016.08.010_bb0145","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jbmr.5650100617","article-title":"Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate","volume":"10","author":"Schweitzer","year":"1995","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2016.08.010_bb0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.bone.2016.08.010_bb0155","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00774-004-0526-y","article-title":"Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia\/osteoporosis","volume":"22","author":"Papadaki","year":"2004","journal-title":"J. Bone Miner. Metab."},{"issue":"8","key":"10.1016\/j.bone.2016.08.010_bb0160","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bone.2016.08.010_bb0165","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.bone.2016.08.010_bb0170","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","article-title":"Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study","volume":"25","author":"Paggiosi","year":"2014","journal-title":"Osteoporos. Int. J. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA."},{"issue":"2","key":"10.1016\/j.bone.2016.08.010_bb0175","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2000.02379.x","article-title":"Characterization of osteoclast precursors in human blood","volume":"111","author":"Shalhoub","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bone.2016.08.010_bb0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2141.1999.01491.x","article-title":"Human osteoclasts derive from CD14-positive monocytes","volume":"106","author":"Massey","year":"1999","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.bone.2016.08.010_bb0185","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1359\/jbmr.2002.17.4.622","article-title":"Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow","volume":"17","author":"Shibata","year":"2002","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2016.08.010_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00223-015-0013-6","article-title":"Biphasic effects of vitamin D and FGF23 on human osteoclast biology","volume":"97","author":"Allard","year":"2015","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2016.08.010_bb0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bone.2008.02.017","article-title":"Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis","volume":"43","author":"D'Amelio","year":"2008","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2016.08.010_bb0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2008-1046787","article-title":"Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial","volume":"40","author":"Anastasilakis","year":"2008","journal-title":"Horm. Metab. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.08.010_bb0205","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/eje.0.1480527","article-title":"Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis","volume":"148","author":"Valleala","year":"2003","journal-title":"Eur. J. Endocrinol. Eur. Fed. Endocr. Soc."},{"issue":"3","key":"10.1016\/j.bone.2016.08.010_bb0210","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/art.10834","article-title":"Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates","volume":"48","author":"Alvarez","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2016.08.010_bb0215","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-015-3174-2","article-title":"Denosumab versus zoledronic acid in patients previously treated with zoledronic acid","author":"Anastasilakis","year":"2015","journal-title":"Osteoporos. Int. J. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA."},{"issue":"4","key":"10.1016\/j.bone.2016.08.010_bb0220","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00774-009-0055-9","article-title":"The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study","volume":"27","author":"Dundar","year":"2009","journal-title":"J. Bone Miner. Metab."},{"issue":"1","key":"10.1016\/j.bone.2016.08.010_bb0225","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)","volume":"19","author":"Pan","year":"2004","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.08.010_bb0230","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","article-title":"Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients","volume":"17","author":"Dobnig","year":"2006","journal-title":"Osteoporos. Int. J. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216302290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216302290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:55:36Z","timestamp":1749059736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216302290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":46,"alternative-id":["S8756328216302290"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.08.010","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}